The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01F | Monoclonal antibodies and antibody drug conjugates | |
| 4 | L01FD | HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors | |
| 5 | L01FD04 | Trastuzumab deruxtecan |
| Active Ingredient | Description | |
|---|---|---|
| Trastuzumab deruxtecan |
Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate. The antibody is a humanised anti-HER2 IgG1 attached to deruxtecan, a topoisomerase I inhibitor (DXd) bound by a tetrapeptide-based cleavable linker. The antibody-drug conjugate is stable in plasma. The function of the antibody portion is to bind to HER2 expressed on the surface of certain tumour cells. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ENHERTU Powder for concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ENHERTU Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
